Coherus Oncology (CHRS) Prepaid Assets (2013 - 2026)
Coherus Oncology (CHRS) posted Prepaid Assets of $2.3 million for Q1 2026, down 66.57% sequentially from $6.8 million in Q4 2025, and down 85.73% YoY from $15.9 million in Q1 2025.
Coherus Oncology (CHRS) Prepaid Assets (2013 - 2026) Analysis & Trends
Coherus Oncology has reported Prepaid Assets for 14 years, with the latest figure at $2.3 million in Q1 2026.
- Quarterly Prepaid Assets fell 85.73% year-over-year to $2.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $2.3 million (down 85.73% YoY) and the FY2025 annual result came in at $6.8 million, up 2.21% from the prior year.
- Prepaid Assets eased to $2.3 million in Q1 2026 per CHRS's latest filing, from $6.8 million in the prior quarter.
- Over five years, Prepaid Assets peaked at $21.0 million in Q1 2023 and troughed at $2.3 million in Q1 2026.
- A 5-year average of $12.9 million and a median of $13.8 million in 2023 frame the typical range for Prepaid Assets.
- The sharpest annual moves came in 2022 and 2026: Prepaid Assets surged 105.49% in 2022, then slumped 85.73% in 2026.
- Over 5 years, Prepaid Assets stood at $17.9 million in 2022, then plunged by 37.93% to $11.1 million in 2023, then tumbled by 40.06% to $6.7 million in 2024, then advanced by 2.21% to $6.8 million in 2025, then sank by 66.57% to $2.3 million in 2026.
- According to Business Quant data, Prepaid Assets over the past three periods registered $2.3 million, $6.8 million, and $8.7 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Coherus Oncology | 221.39 Mn | 116.08 Mn | 10.07 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 5.35 Mn |
| Mar 31, 2026 | 2.27 Mn |
| Dec 31, 2025 | 6.80 Mn |
| Sep 30, 2025 | 8.70 Mn |
| Jun 30, 2025 | 6.70 Mn |
| Mar 31, 2025 | 15.93 Mn |
| Dec 31, 2024 | 6.65 Mn |
| Sep 30, 2024 | 10.70 Mn |
| Jun 30, 2024 | 9.18 Mn |
| Mar 31, 2024 | 14.08 Mn |
| Dec 31, 2023 | 11.10 Mn |
| Sep 30, 2023 | 13.77 Mn |
| Jun 30, 2023 | 17.90 Mn |
| Mar 31, 2023 | 20.95 Mn |
| Dec 31, 2022 | 17.88 Mn |
| Sep 30, 2022 | 20.60 Mn |
| Jun 30, 2022 | 16.67 Mn |
| Mar 31, 2022 | 19.36 Mn |
| Dec 31, 2021 | 13.67 Mn |
| Sep 30, 2021 | 10.03 Mn |